Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoking Cessation Among Native Hawaiians
NCT07075575Not yet recruiting
- Sponsor
- University of Hawaiʻi
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nicotine polacrilex in Tobacco Use Disorder (TUD) (3 arms), sponsored by University of Hawaiʻi. Primary endpoint: 7-day point prevalence abstinence at 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
nicotine polacrilex
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT07075575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075575.